-+ 0.00%
-+ 0.00%
-+ 0.00%

Vertex signs CASGEVY reimbursement agreement in Germany for sickle cell, beta thalassemia

PUBT·05/06/2026 11:16:40
Listen to the news
Vertex signs CASGEVY reimbursement agreement in Germany for sickle cell, beta thalassemia
  • Vertex signed reimbursement agreement with GKV-Spitzenverband for gene-edited therapy CASGEVY in Germany.
  • Deal secures coverage for eligible patients ages 12 and older with severe sickle cell disease or transfusion-dependent beta thalassemia.
  • Germany added to list of reimbursed markets that includes UK, US, Italy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vertex Pharmaceuticals Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20260424009095) on May 06, 2026, and is solely responsible for the information contained therein.